Literature DB >> 34708254

A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.

L Cinnamon Bidwell1,2,3, Hollis C Karoly4,5, Marco Ortiz Torres4, Ashley Master6, Angela D Bryan6, Kent E Hutchison7.   

Abstract

RATIONALE: Published studies examining the effects of cannabis have largely utilized forms of cannabis that are not representative of the legal market products currently available.
OBJECTIVES: The present study aimed to characterize naturalistic use of legal market flower and edible products by examining associations among blood cannabinoids and amount of THC consumed as well as physiological, cognitive, and subjective effects in users of edible and flower forms.
METHOD: Eighty-four participants who used cannabis at least 1 × /week (55 flower cannabis using participants; 29 edible cannabis using participants mean age = 31.95 years, 44% female) participated. At the experimental appointment in our mobile laboratory, participants completed a blood draw to assess plasma cannabinoids, measures of heart rate, subjective drug effects, and cognition both before and after ad libitum use of legal market flower or edible cannabis.
RESULTS: Average self-reported THC consumed was 15.97 mg (SD = 22.40) in edible users and 51.25 mg (SD = 45.23) in flower users. In the edible group, but not the flower group, strong correlations emerged between self-reported ad libitum THC consumed and plasma THC. Plasma THC was significantly higher after use of inhaled cannabis, but similar levels of plasma THC metabolites and similar levels of subjective intoxication and verbal memory impairment were observed in both flower and edible users.
CONCLUSIONS: Findings support strong correlations among ad libitum THC consumed and THC plasma levels after edible cannabis use and suggest few differences in intoxication and impairment between edible and flower cannabis users after ad libitum use. This novel study provides important preliminary data on the pharmacology and effects of legal market edible cannabis.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CBD; Cannabinoids; Drug reward; Edibles; Marijuana; THC

Mesh:

Substances:

Year:  2021        PMID: 34708254     DOI: 10.1007/s00213-021-06007-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans.

Authors:  L D Chait; J P Zacny
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration.

Authors:  Matthew N Newmeyer; Madeleine J Swortwood; Osama A Abulseoud; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2017-03-29       Impact factor: 4.492

Review 3.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

4.  Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration.

Authors:  L Lemberger; J L Weiss; A M Watanabe; I M Galanter; R J Wyatt; P V Cardon
Journal:  N Engl J Med       Date:  1972-03-30       Impact factor: 91.245

5.  Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.

Authors:  Carl L Hart; Amie S Ward; Margaret Haney; Sandra D Comer; Richard W Foltin; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2002-09-14       Impact factor: 4.530

6.  Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.

Authors:  Thomas Nadulski; Frank Sporkert; Martin Schnelle; Andreas M Stadelmann; Patrik Roser; Tom Schefter; Fritz Pragst
Journal:  J Anal Toxicol       Date:  2005 Nov-Dec       Impact factor: 3.367

7.  Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.

Authors:  Amir Englund; Paul D Morrison; Judith Nottage; Dominic Hague; Fergus Kane; Stefania Bonaccorso; James M Stone; Avi Reichenberg; Rudolf Brenneisen; David Holt; Amanda Feilding; Lucy Walker; Robin M Murray; Shitij Kapur
Journal:  J Psychopharmacol       Date:  2012-10-05       Impact factor: 4.153

8.  Effects of THC on behavioral measures of impulsivity in humans.

Authors:  Jennifer McDonald; Laura Schleifer; Jerry B Richards; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2003-04-30       Impact factor: 7.853

9.  A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains.

Authors:  L Cinnamon Bidwell; Raeghan Mueller; Sophie L YorkWilliams; Sarah Hagerty; Angela D Bryan; Kent E Hutchison
Journal:  Cannabis Cannabinoid Res       Date:  2018-03-01
View more
  1 in total

Review 1.  Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

Authors:  Jolanta Weresa; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Barbara Malinowska; Eberhard Schlicker
Journal:  Cells       Date:  2022-03-28       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.